3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
13
Pancreatic Neoplasms
5
Non-Squamous Non-Small Cell Lung Cancer
5
Neoplasms
4
Colorectal Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Diseases
2
Neoplasm Metastasis
2
Carcinoma
2
Brain Neoplasms
2
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Rectal Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Non-squamous Non-small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
NSCLC
1
Mouth Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Carboplatin
4
Pemetrexed
3
pembrolizumab
2
Paclitaxel
2
Cisplatin
2
Bevacizumab
2
icotinib
1
Platinum
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Non-squamous Non-small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Clear all
NCT02633189
2023-03-24
BEVERLY
National Cancer Institute, Naples
Phase 3
Unknown
200 enrolled